Werewolf Therapeutics, Inc. (HOWL) Tops Q4 EPS by 16c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q4 EPS of ($0.39), $0.16 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $2.07 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 36c
• Bank of the James (BOTJ) Tops Q2 EPS by 71c
• Pathfinder Bancorp (PBHC) Tops Q2 EPS by 42c